Monoclonal antibodies for North Ostrobothnia welfare area 2027-2028
Original notice title
Monoklonaaliset vasta-aineet ajalle 1.1.-31.12.2027 + optiovuosi 2028 Pohjois-Pohjanmaan hyvinvointialueelle
Opportunity Score
Why this score?
Opportunity
30 / 100
Complexity
50 / 100
Risk factors
The total contract value is unknown, which may affect resource allocation and competitiveness of bids.
The structured data contains two lots, but the second lot lacks essential details (description, CPV, deadline). The XML...
Submission deadline in 0 days
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 2 lots
- Duration 24 MONTH
- Supply of monoclonal antibodies and antibody-conjugated drugs classified under ATC group L01F.
- Products must have a marketing authorization in Finland and be commercially available by January 1, 2027.
Show full summary
This tender from Pohjois-Pohjanmaan hyvinvointialue (North Ostrobothnia welfare area) is for the supply of monoclonal antibodies and antibody-conjugated drugs (ATC group L01F) for the period 1.1.2027–31.12.2027 with an optional extension year (2028). The procedure is open, with electronic submission required via Kilpo.fi. The tender is awarded based on price (70%) and quality (30%). Only one lot is explicitly described in the structured data, but a second lot appears with incomplete information. No estimated value is provided. Submissions are accepted only in Finnish. The structured data includes two lots, but the XML notice references only one lot, indicating a potential extraction issue. No procurement documents beyond the notice were analyzed.
Risks
The total contract value is unknown, which may affect resource allocation and competitiveness of bids.
The structured data contains two lots, but the second lot lacks essential details (description, CPV, deadline). The XML...
Submission deadline in 0 days
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Marketing authorization in Finland required by the start of the contract period.
- Products must be commercially available in Finland by 1.1.2027.
Administrative
- Electronic submission via Kilpo.fi is mandatory.
Award Criteria
Lot 1
Buyer
Name
Pohjois-Pohjanmaan hyvinvointialue
Location
POHDE, FIN
Identifier
3221326-2
Lots (2)
LOT-0000
Monoklonaaliset vasta-aineet ajalle 1.1.-31.12.2027 + optiovuosi 2028 Pohjois-Pohjanmaan hyvinvointialueelle
Procurement of monoclonal antibodies and antibody-conjugated drugs in ATC group L01F. Products must have marketing authorization in Finland and be commercially available by 1.1.2027. Products with ongoing authorization processes are eligible if completed before the start of the contract period.
Location
Duration
Category
Selection criteria
Deadline
Award details
Show original TED data
Original TED description
Hankinnan kohteena ovat monoklonaaliset vasta-aineet ja vasta-ainekonjugoidut lääkkeet, jotka kuuluvat ATC-ryhmään L01F. Tarjotuilla lääkevalmisteilla tulee olla myyntilupa Suomessa ja niiden tulee olla Suomessa kaupan ja saatavilla 1.1.2027. Hankinta koskee myös lääkevalmisteita, joiden myyntilupaprosessi, rinnakkaistuontilupa tai rinnakkaisjakelun ilmoitusprosessi on kesken, mutta myyntilupa tai rinnakkaistuontilupa myönnetään tai rinnakkaisjakeluilmoitus hyväksytään ennen hankintakauden alkamista ja tuotteet ovat kaupan ja saatavilla Suomessa viimeistään 1.1.2027.
Lot 2
Lot 2
Lot information incomplete in structured data. Only award criteria (quality) provided; no description, CPV, or deadline available.
Procurement Details
- Publication date
- 21 May 2026
- Notice type
- Contract notice — standard
- Languages
- Finnish
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 351390-2026
- Source notice ID
- 168eb57b-fa3a-490f-8213-4fc0049719e1
Documents (1)
Similar tenders
Denmark – Pharmaceutical products – Amgros 2027 1.1051.b
Poland – Pharmaceutical products – Dostawa produktów leczniczych do SPZZOZ w Wyszkowie
Romania – Pharmaceutical products – MEDICAMENTE - PRODUSE FARMACEUTICE
Denmark – Pharmaceutical products – Amgros 2027 1.1052.b
Latvia – Pharmaceutical products – Par reģistrēto un nereģistrēto medikamentu piegādi Elektronisko iepirkumu sistēmas dalībniekiem
Spain – Pharmaceutical products – Suministro de Aflibercept (DOE) Intravítreo 40 mg/ml
Opportunity Score
Why this score?
Opportunity
30 / 100
Complexity
50 / 100
Risk factors
The total contract value is unknown, which may affect resource allocation and competitiveness of bids.
The structured data contains two lots, but the second lot lacks essential details (description, CPV, deadline). The XML...
Submission deadline in 0 days
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications